ICD-10-CM Code C43.9

Malignant melanoma of skin, unspecified

Version 2020 Billable Code

Valid for Submission

C43.9 is a billable code used to specify a medical diagnosis of malignant melanoma of skin, unspecified. The code is valid for the year 2020 for the submission of HIPAA-covered transactions. The ICD-10-CM code C43.9 might also be used to specify conditions or terms like acral lentiginous malignant melanoma of skin, adverse effect from puva photochemotherapy, amelanotic malignant melanoma of skin, balloon cell malignant melanoma, borderline malignant melanoma, clark melanoma level 1, etc

ICD-10:C43.9
Short Description:Malignant melanoma of skin, unspecified
Long Description:Malignant melanoma of skin, unspecified

Tabular List of Diseases and Injuries

The Tabular List of Diseases and Injuries is a list of ICD-10 codes, organized "head to toe" into chapters and sections with guidance for inclusions, exclusions, descriptions and more. The following references are applicable to the code C43.9:

Inclusion Terms

Inclusion Terms
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
  • Malignant melanoma of unspecified site of skin
  • Melanoma (malignant) NOS

Index to Diseases and Injuries

The Index to Diseases and Injuries is an alphabetical listing of medical terms, with each term mapped to one or more ICD-10 code(s). The following references for the code C43.9 are found in the index:


Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Acral lentiginous malignant melanoma of skin
  • Adverse effect from PUVA photochemotherapy
  • Amelanotic malignant melanoma of skin
  • Balloon cell malignant melanoma
  • Borderline malignant melanoma
  • Clark melanoma level 1
  • Clark melanoma level 2
  • Clark melanoma level 3
  • Clark melanoma level 4
  • Clark melanoma level 5
  • Clark melanoma level finding
  • Clark melanoma level finding
  • Clark melanoma level finding
  • Clark melanoma level finding
  • Clark melanoma level finding
  • Congenital malignant melanoma
  • Congenital pigmented melanocytic nevus of skin
  • Desmoplastic malignant melanoma
  • Donor derived melanoma
  • Familial malignant melanoma of skin
  • Hypermelanosis due to neoplasia
  • Hypomelanosis surrounding malignant melanoma
  • Hypomelanosis surrounding melanocytic neoplasm
  • Lentigo maligna melanoma
  • Local recurrence of malignant melanoma of skin
  • Malignant blue nevus of skin
  • Malignant melanoma
  • Malignant melanoma
  • Malignant melanoma
  • Malignant melanoma animal-type
  • Malignant melanoma arising in congenital nevus
  • Malignant melanoma arising in intradermal nevus
  • Malignant melanoma metastatic to kidney
  • Malignant melanoma metastatic to pancreas
  • Malignant melanoma of nail apparatus
  • Malignant melanoma of skin
  • Malignant neoplasm of nail apparatus
  • Materno-fetal metastatic malignant melanoma
  • Melanoma and neural system tumor syndrome
  • Melanoma carcinomatosis
  • Metastasis from malignant melanoma of skin
  • Metastatic malignant melanoma
  • Metastatic malignant melanoma
  • Metastatic malignant melanoma
  • Metastatic malignant melanoma
  • Metastatic malignant melanoma with diffuse hypermelanosis
  • Neurotropic malignant melanoma
  • Nodular malignant melanoma of skin
  • pM1a: Metastasis to skin, subcutaneous tissues, or distant lymph nodes
  • pM1b: Metastasis to lung
  • pM1c category
  • pM1c: Metastasis to visceral site other than lung or distant metastasis at any site associated with an elevated serum lactic dehydrogenase
  • pN1: Metastasis in one regional lymph node
  • pN1a category
  • pN1a: Clinically occult
  • pN1b category
  • pN1b: Clinically apparent
  • pN2: Metastasis in 2 to 3 regional nodes or intralymphatic regional metastasis without nodal metastasis
  • pN2a category
  • pN2a: Clinically occult
  • pN2b category
  • pN2b: Clinically apparent
  • pN2c category
  • pN2c: Satellite or in-transit metastasis without nodal metastasis
  • pN3: Metastasis in four or more regional nodes, or matted metastatic nodes, or in-transit metastasis or satellite
  • pT1: Melanoma 1.0 mm or less in thickness, with or without ulceration
  • pT1a: Melanoma 1.0 mm or less in thickness and level II or III, no ulceration
  • pT1b: Melanoma 1.0 mm or less in thickness and level IV or V or with ulceration
  • pT2: Melanoma 1.01 to 2.0 mm in thickness, with or without ulceration
  • pT2a: Melanoma 1.01 to 2.0 mm in thickness, no ulceration
  • pT2b: Melanoma 1.01 to 2.0 mm in thickness, with ulceration
  • pT3: Melanoma 2.01 to 4.0 mm in thickness, with or without ulceration
  • pT3a: Melanoma 2.01 to 4.0 mm in thickness, no ulceration
  • pT3b: Melanoma 2.01 to 4.0 mm in thickness, with ulceration
  • pT4: Melanoma greater than 4.0 mm in thickness, with or without ulceration
  • pT4a: Melanoma greater than 4.0 mm in thickness, no ulceration
  • pT4b: Melanoma greater than 4.0 mm in thickness, with ulceration
  • PUVA therapy-associated malignant melanoma
  • PUVA therapy-associated skin malignancy
  • Secondary malignant neoplasm of kidney
  • Secondary malignant neoplasm of pancreas
  • Spindle cell malignant melanoma
  • Superficial spreading malignant melanoma of skin
  • Surgical deep margin involved by malignant melanoma
  • Surgical deep margin involved by malignant neoplasm
  • Surgical deep margin involvement by melanoma cannot be assessed
  • Surgical deep margin uninvolved by malignant melanoma
  • Surgical lateral margin involved by malignant melanoma
  • Surgical lateral margin involvement by melanoma cannot be assessed
  • Surgical lateral margin uninvolved by malignant melanoma
  • Widespread metastatic malignant neoplastic disease

Diagnostic Related Groups

The ICD-10 code C43.9 is grouped in the following groups for version MS-DRG V37.0 What are Diagnostic Related Groups?
The Diagnostic Related Groups (DRGs) are a patient classification scheme which provides a means of relating the type of patients a hospital treats. The DRGs divides all possible principal diagnoses into mutually exclusive principal diagnosis areas referred to as Major Diagnostic Categories (MDC).
applicable from 10/01/2020 through 09/30/2020.

  • 595 - MAJOR SKIN DISORDERS WITH MCC
  • 596 - MAJOR SKIN DISORDERS WITHOUT MCC

Convert C43.9 to ICD-9

  • 172.9 - Malig melanoma skin NOS (Approximate Flag)

Code Classification

  • Neoplasms (C00–D48)
    • Melanoma and other malignant neoplasms of skin (C43-C44)
      • Malignant melanoma of skin (C43)

Code History

  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
    (First year ICD-10-CM implemented into the HIPAA code set)
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020

Information for Patients


Melanoma

Melanoma is the most serious type of skin cancer. Often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. Most melanomas have a black or black-blue area. Melanoma may also appear as a new mole. It may be black, abnormal, or "ugly looking."

Thinking of "ABCDE" can help you remember what to watch for:

  • Asymmetry - the shape of one half does not match the other
  • Border - the edges are ragged, blurred or irregular
  • Color - the color is uneven and may include shades of black, brown and tan
  • Diameter - there is a change in size, usually an increase
  • Evolving - the mole has changed over the past few weeks or months

Surgery is the first treatment of all stages of melanoma. Other treatments include chemotherapy and radiation, biologic, and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells.

NIH: National Cancer Institute


[Learn More]